Optimal anesthesia for bladder cancer surgery using 5-aminolevulinic acid

Optimal anesthesia for bladder cancer surgery using 5-aminolevulinic acid - Optimal anesthesia for bladder cancer surgery using 5-aminolevulinic acid

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059195

Enrollment

425

Registered

2025-09-25

Start date

2025-09-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We will review the medical records and anesthesia records preserved at our hospital from January 1, 2018, to December 31, 2024, for patients who underwent bladder cancer surgery using 5-aminolevulinic acid (5-ALA) during this period. From these records, we will extract data on anesthesia methods and intraoperative blood pressure values to detect the frequency and severity of intraoperative hypotension. Patients will be categorized into three groups based on anesthesia method: general anesthesia, general anesthesia with remimazolam, and spinal anesthesia. The extracted hypotensive events will then be analyzed within each group to evaluate the primary and secondary endpoints.

Exclusion criteria

Exclusion criteria: non

Design outcomes

Primary

Measure	Time frame
Frequency and severity of intraoperative hypotension	—

Secondary

Measure	Time frame
Frequency of Use of Hypertensive Drugs	—

Countries

Japan

Contacts

Public ContactYoshifumi Katsumata

Kochi University Department of Anesthesiology and Intensive Care Medicine, Kochi medical school

katsu1206@kochi-u.ac.jp088-880-2471

Outcome results